GSK Reaches ‘First Base’ In Hep B Functional Cure But Has More To Prove
9% Disease Free After Phase II Study
GSK is the first to raise the functional cure rate with its antisense drug, Phase II data suggest, but the company is looking for ways to boost responses across hepatitis B patients in its Phase III study.
